Zimbabwe has declined a significant American healthcare agreement worth $367m (£272m) spanning five years because of Washington's request for confidential biological samples.
This rejection came to light following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesman has since stated that the US was demanding access to biological samples for scientific study and commercial purposes but refused to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued talks to secure a deal acceptable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable situation in Kenya, where a court suspended a similar health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and accountability.
As per reports, 16 African countries have so far signed these new health pacts, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the end products would be available to our citizens should a future health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were upending systems already set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This framework is intended to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future collaboration might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but suggested that talks should continue considering much of the country's HIV programmes were funded by foreign aid.
"Where specific concerns exist, such as those relating to information security or agreement terms, these can frequently be resolved through technical clarification and negotiated safeguards," the group said.
The situation emphasises the continuing debate between receiving crucial international aid and safeguarding a country's data in an ever more data-driven world.